Ryan N Hansen1, Denise M Boudreau1, Beth E Ebel1, David C Grossman1, Sean D Sullivan1. 1. Ryan N. Hansen, Denise M. Boudreau, and Sean D. Sullivan are with the Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle. Denise M. Boudreau is also with and David C. Grossman is with the Group Health Research Institute, Seattle. Beth E. Ebel is with the Harborview Injury Prevention and Research Center, Seattle, and the Departments of Pediatrics and Epidemiology, and Health Services, University of Washington. David C. Grossman and Sean D. Sullivan are also with the Department of Health Services, University of Washington.
Abstract
OBJECTIVES: We sought to estimate the association between sedative hypnotic use and motor vehicle crash risk. METHODS: We conducted a new user cohort study of 409 171 adults in an integrated health care system. Health plan data were linked to driver license and collision records. Participants were aged 21 years or older, licensed to drive in Washington State, had at least 1 year of continuous enrollment between 2003 and 2008, and were followed until death, disenrollment, or study end. We used proportional hazards regression to estimate the risk of crash associated with 3 sedatives. RESULTS: We found 5.8% of patients received new sedative prescriptions, with 11 197 person-years of exposure. New users of sedatives were associated with an increased risk of crash relative to nonuse: temazepam hazard ratio (HR) = 1.27 (95% confidence interval [CI] = 0.85, 1.91), trazodone HR = 1.91 (95% CI = 1.62, 2.25), and zolpidem HR = 2.20 (95% CI = 1.64, 2.95). These risk estimates are equivalent to blood alcohol concentration levels between 0.06% and 0.11%. CONCLUSIONS: New use of sedative hypnotics is associated with increased motor vehicle crash risk. Clinicians initiating sedative hypnotic treatment should consider length of treatment and counseling on driving risk.
OBJECTIVES: We sought to estimate the association between sedative hypnotic use and motor vehicle crash risk. METHODS: We conducted a new user cohort study of 409 171 adults in an integrated health care system. Health plan data were linked to driver license and collision records. Participants were aged 21 years or older, licensed to drive in Washington State, had at least 1 year of continuous enrollment between 2003 and 2008, and were followed until death, disenrollment, or study end. We used proportional hazards regression to estimate the risk of crash associated with 3 sedatives. RESULTS: We found 5.8% of patients received new sedative prescriptions, with 11 197 person-years of exposure. New users of sedatives were associated with an increased risk of crash relative to nonuse: temazepam hazard ratio (HR) = 1.27 (95% confidence interval [CI] = 0.85, 1.91), trazodone HR = 1.91 (95% CI = 1.62, 2.25), and zolpidem HR = 2.20 (95% CI = 1.64, 2.95). These risk estimates are equivalent to blood alcohol concentration levels between 0.06% and 0.11%. CONCLUSIONS: New use of sedative hypnotics is associated with increased motor vehicle crash risk. Clinicians initiating sedative hypnotic treatment should consider length of treatment and counseling on driving risk.
Authors: Denise M Boudreau; Onchee Yu; Jessica Chubak; Heidi S Wirtz; Erin J Aiello Bowles; Monica Fujii; Diana S M Buist Journal: Breast Cancer Res Treat Date: 2014-02-21 Impact factor: 4.872
Authors: B M Psaty; S R Heckbert; T D Koepsell; D S Siscovick; T E Raghunathan; N S Weiss; F R Rosendaal; R N Lemaitre; N L Smith; P W Wahl Journal: JAMA Date: 1995 Aug 23-30 Impact factor: 56.272
Authors: Jacob T Borodovsky; Melissa J Krauss; Tingying Chi; Laura J Bierut; Richard A Grucza Journal: Alcohol Clin Exp Res Date: 2019-05-28 Impact factor: 3.455
Authors: Laura A Fraade-Blanar; Ryan N Hansen; Kwun Chuen G Chan; Jeanne M Sears; Hilaire J Thompson; Paul K Crane; Beth E Ebel Journal: Accid Anal Prev Date: 2018-03-07
Authors: Laura A Fraade-Blanar; Beth E Ebel; Eric B Larson; Jeanne M Sears; Hilaire J Thompson; Kwun Chuen G Chan; Paul K Crane Journal: J Am Geriatr Soc Date: 2018-04-17 Impact factor: 5.562